Sanbexin sublingual (edaravone dexborneol sublingual) / Yantai YenePharma, Simcere, NeuroDawn 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  Sanbexin sublingual (edaravone dexborneol sublingual) / Yantai YenePharma, Simcere, NeuroDawn, Sanbexin (edaravone dexborneol) / Simcere
    Trial completion date, Trial primary completion date:  Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients (clinicaltrials.gov) -  Sep 20, 2024   
    P2,  N=80, Recruiting, 
    Trial completion date: May 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
  • ||||||||||  Sanbexin sublingual (edaravone dexborneol sublingual) / Yantai YenePharma, Simcere, NeuroDawn, Sanbexin (edaravone dexborneol) / Simcere
    Enrollment open:  Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients (clinicaltrials.gov) -  Jun 11, 2024   
    P2,  N=80, Recruiting, 
    Trial completion date: May 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025 Not yet recruiting --> Recruiting
  • ||||||||||  Sanbexin sublingual (edaravone dexborneol sublingual) / Yantai YenePharma, Simcere, NeuroDawn
    Journal:  Longitudinal evaluation of major salivary gland functioning in Sj (Pubmed Central) -  Dec 31, 2023   
    ClinicalTrials.gov Identifier: NCT04950920. Overall, major salivary gland functioning assessed with SGUS, sialometry and PROMs did not change significantly up to 5 years of follow-up in a standard-of-care cohort of SjD patients from daily clinical practice.
  • ||||||||||  Sanbexin sublingual (edaravone dexborneol sublingual) / Yantai YenePharma, Simcere, NeuroDawn
    Trial completion:  A Study to Evaluate the Pharmacokinetics,Safety and Tolerability of Y-2 Sublingual Tablet in Healthy Adult Subjects (clinicaltrials.gov) -  Dec 12, 2023   
    P1,  N=36, Completed, 
    Overall, major salivary gland functioning assessed with SGUS, sialometry and PROMs did not change significantly up to 5 years of follow-up in a standard-of-care cohort of SjD patients from daily clinical practice. Not yet recruiting --> Completed
  • ||||||||||  Sanbexin sublingual (edaravone dexborneol sublingual) / Yantai YenePharma, Simcere, NeuroDawn
    Trial completion, Trial completion date, Trial primary completion date:  Phase III Clinical Trial of Y-2 Sublingual Tablets in the Treatment of Acute Ischemic Stroke (clinicaltrials.gov) -  Dec 14, 2022   
    P3,  N=914, Completed, 
    Not yet recruiting --> Completed Recruiting --> Completed | Trial completion date: Mar 2022 --> Nov 2022 | Trial primary completion date: Dec 2021 --> Aug 2022
  • ||||||||||  Sanbexin sublingual (edaravone dexborneol sublingual) / Yantai YenePharma, Simcere, NeuroDawn
    Trial completion date, Trial primary completion date:  Safety, Tolerability and Pharmacokinetics of Y-2(Edaravone And Borneol) Sublingual Tablet (clinicaltrials.gov) -  Feb 17, 2020   
    P1,  N=24, Recruiting, 
    Recruiting --> Completed | Trial completion date: Mar 2022 --> Nov 2022 | Trial primary completion date: Dec 2021 --> Aug 2022 Trial completion date: Mar 2019 --> Feb 2021 | Trial primary completion date: Jan 2019 --> Dec 2020
  • ||||||||||  Sanbexin sublingual (edaravone dexborneol sublingual) / Yantai YenePharma, Simcere, NeuroDawn
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date:  Safety, Tolerability and Pharmacokinetics of Y-2(Edaravone And Borneol) Sublingual Tablet (clinicaltrials.gov) -  Nov 5, 2018   
    P1,  N=24, Recruiting, 
    Trial completion date: Mar 2019 --> Feb 2021 | Trial primary completion date: Jan 2019 --> Dec 2020 Not yet recruiting --> Recruiting | Trial completion date: Oct 2018 --> Mar 2019 | Initiation date: Apr 2018 --> Oct 2018 | Trial primary completion date: Aug 2018 --> Jan 2019